BioWorld

Oct. 11, 2010

Reading the Tea Leaves for Interferon's Future in HCV

Last week's complete response letter for Human Genome Sciences Inc. and Novartis AG's Zalbin (albinterferon alfa-2b) came as no surprise given the hepatitis C drug's history. Read More

Money Raised Year to Date

More Pharma-Dumped Assets Coming Back Home to Biotech

When the Going Gets Tough, the Tough Reverse Stock Split

Money Raised By Biotech in 2010

Week in Review

Word on the Street

Week in Washington

Phase I Clinical Trials Update: September 2010

FDA Approvals in September

Phase II Clinical Trials Update: September 2010

Phase III Clinical Trials Update: September 2010

Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Non-U.S. Clinical Trials & Regulatory Actions: Sept. 2010

FDA Submissions, Approvals & Other Actions: Sept. 2010

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 18, 2025.

An early stage 85% remissions rate in AML drives Aptevo’s stock surge

BioWorld

An 85% remissions rate was found in updated results from Aptevo Therapeutics Inc.’s ongoing phase Ib/II Ranier study of mipletamig in one of the toughest blood...

BIO 2025: Makary lays out FDA’s path, launches pilot review program

BioWorld

On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...

3D illustration of a chain of amino acid or biomolecules called protein

Alphadesign: AI creating proteins from scratch

BioWorld Science

The Alphafold machine learning system for predicting a protein’s structure from its amino acid sequence has been adapted to make it possible to design de novo...